Replies to post #123719 on Biotech Values

[DewDiligence]

AGN’s CEO, David Pyott, said on today’s CC that Merz’s delay in launching Xeomin for cosmetic indications is due to a manufacturing glitch. If true, this answers the question I asked in the second-from-bottom paragraph of #msg-65423443.